Lung Cancer Clinical Trials & Research at Providence Medical Group
The two main types of lung cancer are non-small cell lung cancer and small
cell lung cancer. The types are based on the way the cells look under
a microscope. Non-small cell lung cancer is much more common than small
cell lung cancer. Tobacco smoking is the most common cause of lung cancer.
Providence Medical Group is currently enrolling patients for the following
lung cancer clinical trials:
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Study to Assess the Effect of PF_06946860 on Appetite Following Subcutaneous
Administration to Patients with Anorexia and Advanced Cancer
Treatment agent: PF-06946860
PI: Sara Keck, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707)
521-3833 ext. 1313
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04803305?term=PF-06946860&draw=2&rank=2
Sponsor: Pfizer
Non-Small Cell Lung Cancer
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients
with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Treatment agent: MRTX849 + pembrolizumab
PI:
Manasa Vulchi, MD
Study Coordinator: Tracy Foster
Resources and Links:
clinicaltrials.gov NCT No: NCT04613596
Sponsor: Mirati Therapeutics, Inc.
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants
With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)
Treatment agent: Zimberelimab with or without domvanalimab and/or etrumadenant
PI:
Ian Anderson, MD
Study Coordinator: Camille Shaffer
Resources and Links:
clinicaltrials.gov NCT No: NCT04262856
Sponsor: Arcus Biosciences, Inc.
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled
Study to Determine the Efficacy of Adjuvant Durvalumab in Combination
with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC
(MeRmaiD-1)
Treatment agent: Durvalumab + chemotherapy
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT04385368
Sponsor: AstraZeneca
A Phase III, Open-label, Randomized Study of Osimertinib with or without
Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients
with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally
Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)
Treatment agent: Osimertinib with or without platinum-based chemotherapy
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT04035486
Sponsor: AstraZeneca
Phase 2 Platform Study in Patients with advanced non-small lung cancer
who progressed on First Line Osimertinib therapy (ORCHARD)
Treatment agent: Osimertinib
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT03944772
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase
Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo
with Pembrolizumab and Chemotherapy in First-Line, Metastic KEAP1/NRF2-Mutated,
Nonsquamous, Non-Small Cell Lung Cancer (KEAPSAKE CX-839-014)
Treatment agent: Telaglenastat/ placebo + SOC
PI:
Ian Anderson, MD
Study Coordinator: Teresa
Resources and Links:
clinicaltrials.gov No: NCT04265534
Small Cell Lung Cancer
A phase III, multicenter, randomized, double blind, placebo-controlled
study evaluating the efficacy and safety of canakinumab versus placebo
as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA
and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
Treatment agent: Canakinumab or Placebo
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT03447769?term=03447769&draw=2&rank=1
Sponsor: Novartis Pharmaceuticals
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled
Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with
Minimal Residual Disease Following Surgery and Curative Intent Therapy
(MERMAID-2)
Treatment agent: Durvalumab or placebo
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04642469?term=04642469&draw=2&rank=1
Sponsor: AstraZeneca
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and
Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable
and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless
of Tumor Histology
Treatment agent: Berzosertib, Topotecan Hydrochloride
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT03896503?term=03896503&draw=2&rank=1
Sponsor: EMD Serono
Seer-020201 (Pulmonary Nodules)
Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI:
Manasa Vulchi, MD
Study Coordinator: Melissa
NCT – NA